NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data
This first real-world analysis of NALIRIFOX confirms its clinical effectiveness and manageable toxicity in an unselected patient population. The favorable outcomes in HRRm subgroups and the prognostic impact of KRAS variants underscore the need for molecular stratification in guiding first-line therapy for mPDAC.
Authors
- Bernhard Doleschal (ORCID: https://orcid.org/0009-0004-4813-4435)
- Hossein Taghizadeh (ORCID: https://orcid.org/0000-0002-0927-6498)
- Theresa Lentner (ORCID: https://orcid.org/0009-0005-4381-7605)
- Gerald Webersinke (ORCID: https://orcid.org/0000-0001-5654-6190)
- A. Friedrich (ORCID: https://orcid.org/0000-0002-4587-7901)
- Gerald W. Prager (ORCID: https://orcid.org/0000-0002-7854-7781)
- P. Reimann (ORCID: https://orcid.org/0000-0002-6355-4591)
- Holger F. Rumpold (ORCID: https://orcid.org/0000-0002-4118-0111)
- David Nothdurfter
- Patrick Kirchweger (ORCID: https://orcid.org/0000-0003-2806-4594)
- Andreas Reichinger (ORCID: https://orcid.org/0000-0002-2835-5634)
- Hannes Windhager
- Jonathan Burghofer (ORCID: https://orcid.org/0000-0001-6720-4671)
- Thomas Winder (ORCID: https://orcid.org/0000-0003-4651-5758)
Institutions
- Johannes Kepler University of Linz (AT)
- Landeskrankenhaus Feldkirch (AT)
- Universitätsklinikum St. Pölten (AT)
- Kepler Universitätsklinikum (AT)
- Private University in the Principality of Liechtenstein (LI)
- AGO Austria (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105827
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05